Sonneveld P, Moreau P, Einsele H, Quach H, Ho P, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Pei H, Sitthi-Amorn A, Carson R, Rodríguez-Otero P, Dimopoulos M, Boccadoro M. P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE. haematol [Internet]. 2026Apr.15 [cited 2026Apr.21];111(s2). Available from: https://haematologica.org/article/view/haematol.2026.s2.14037